Use of fecal occult blood test up during pandemic; more than half of respondents willing to do at-home FOBT in lieu of colonoscopy
TUESDAY, Oct. 26, 2021 (HealthDay News) — Colonoscopy rates were similar during versus before the COVID-19 pandemic, but use of the fecal occult blood test (FOBT) increased, according to a study presented at the annual meeting of the American College of Surgeons, held virtually from Oct. 23 to 27.
Kristine Kenning, M.D., from the Virginia Commonwealth University Medical Center in Richmond, and colleagues conducted a cross-sectional study involving 745 individuals to examine attitudes toward colorectal cancer screening during the pandemic.
The researchers found that respondents had higher completion of FOBT in the previous three years than American Cancer Society-reported FOBT use pre-COVID-19 (32 versus 11 percent); during the pandemic, 50 percent of respondents completed FOBT. Compared with pre-COVID-19 rates, respondents had higher unemployment rates (7.4 versus 2.6 percent). When scheduling colonoscopies, respondents confirmed concerns about copays and COVID-19 (41 and 65.9 percent, respectively). Some of those who had concerns reported that this delayed their screening. The likelihood of colonoscopy was increased with offerings of gloves and masks, smaller offices, and weekend screening. In lieu of colonoscopy, 48.1 percent of respondents were willing to do an at-home FOBT. If the FOBT was positive, 93.0 percent would be willing to do a follow-up colonoscopy.
“Our study found that people are compliant with, and willing to do, home-based fecal occult blood testing,” Kenning said in a statement. “This test provides a very important way for us to increase screening for colorectal cancer.”
Urine Cell-Free RNA Shows Promise as Biomarker for Bladder Cancer
Age-, Joint-Specific Ultrasound Reference Values Set for Healthy Joints
Surveillance Colonoscopy at Five Years After Adenoma Removal Noninferior to Three Years
Family History of CRC Increases CRC Risk Similarly in IBD, General Population
Personalized Support Boosts Families" Genetic Testing for Hereditary Cancers
Serum 25(OH)D May Serve as Biomarker of Disease Activity in IBD
Gene Mutation Identified That Increases Lung Cancer Risk
Genetics, Diabetes Tied to MASLD-Associated Cirrhosis Before Age 50